Video

Dr. Salani on Patient Selection for Primary Debulking Surgery in Ovarian Cancer

Author(s):

Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.

Ritu Salani, MD, gynecologic oncologist, associate professor, Department of Obstetrics and Gynecology, director, Gynecologic Oncology Fellowship Program, The Ohio State University Wexner Medical Center, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.

The first primary endpoint to consider when comparing the outcomes of neoadjuvant chemotherapy and primary debulking surgery is survival outcomes, which have been approximately similar, explains Salani. However, there are a few issues with both treatment modalities that have been challenged in studies, according to Salani.

Individual selection rather than a one-size-fits-all approach is key when choosing to give a patient neoadjuvant chemotherapy or primary debulking surgery, says Salani. The main difference between the options is surgical complications. Primary debulking surgery is often more involved, creating a higher complication rate. If the right patients are chosen, primary debulking surgery can be performed safely, but patients must be considered carefully, concludes Salani.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity